On WSJ Pharmalot, Ed Silverman gets experts to comment on the pharmaceutical company AstraZeneca’s latest way of attempting to comply with growing public pressure to disclose data from drug trials for independent researchers to review.
“The move comes as the pharmaceutical industry grapples over the extent to which data should be disclosed in the wake of scandals over safety or effectiveness data that was not publicly shared,” writes Silverman. “The move by AstraZeneca was largely praised by academics who have been pressuring the industry to release data, although they also questioned the independence of the review board. Of the four members, two of the scientists have acknowledged that they did consulting work for AstraZeneca over the past few years.”
AstraZeneca to Disclose Trial Data, but how Independent is its Review Panel? (WSJ Pharmalot, March 24, 2015)
